Abstract
Bosentan was approved for therapy of pulmonary arterial hypertension and reduction of new digital ulcers associated with systemic sclerosis. Two randomized placebo-controlled multicenter clinical trials have shown that bosentan reduces number of new digital ulcers but does not induce healing of present defects.
In patients with pulmonary arterial hypertension bosentan leads to improvement of functional capacity and especiallyimprovement of their prognosis.